NCT06793917 2025-07-20Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction AdenocarcinomaFujian Cancer HospitalPhase 3 Recruiting269 enrolled